Reversible sulfasalazine-induced granulomatous hepatitis

Area of Science:

• Hepatology
• Gastroenterology
• Pharmacology

Background:

• Sulfasalazine is a widely prescribed medication for inflammatory bowel disease (IBD).
• Drug-induced liver injury (DILI) is a potential adverse effect of many medications, including sulfasalazine.
• Granulomatous hepatitis is a specific pattern of liver inflammation characterized by granulomas.

Observation:

• A patient with inflammatory bowel disease developed documented granulomatous hepatitis.
• The liver biopsy confirmed the presence of granulomas.
• The patient's condition was linked to sulfasalazine treatment.

Findings:

• Discontinuation of sulfasalazine led to the resolution of granulomatous hepatitis.
• Liver biopsy 6 weeks post-cessation showed resolution of the inflammatory process.
• This suggests a causal link between sulfasalazine and the observed liver damage.

Implications:

• Clinicians should consider sulfasalazine as a potential cause of granulomatous hepatitis in IBD patients.
• Early recognition and drug withdrawal are crucial for managing sulfasalazine-induced liver injury.
• This case highlights the importance of monitoring liver function in patients receiving long-term sulfasalazine therapy.